Skip to main content

Novel Rx

      RT @RichardPAConway: Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons

      Richard Conway RichardPAConway

      4 years 10 months ago
      Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm
      Here are my highlights from day three, Sunday, of the ACR 2020 Convergence. 
      RT @RichardPAConway: Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greate

      Richard Conway RichardPAConway

      4 years 10 months ago
      Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
      RT @drdavidliew: Tocilizumab in GCA: what happens in the vessels?

      Supporting excellent work @KQuinnRheum @petercgrayson

      David Liew drdavidliew

      4 years 10 months ago
      Tocilizumab in GCA: what happens in the vessels? Supporting excellent work @KQuinnRheum @petercgrayson earlier at #ACR20, LV-GCA data from Blanco/Gonzalez-Gay et al. Aorta still hot at 10.8±3.7 mo. in LV-GCA on TCZ, clinical remission ≠ PET remission #ACR20 ABST1921 @RheumNow https://t.co/ngBVL4rop8
      RT @ejdein1: SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general hea

      Eric Dein ejdein1

      4 years 10 months ago
      SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
      RT @DrPetryna: @rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 a

      Olga Petryna DrPetryna

      4 years 10 months ago
      @rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts
      GCA Treatment Data: Dr. David Liew Abstract

       

      Dr. David Liew reviews abstracts #0516 and #0513 presented at the 2020 ACR annual meeting.

      RT @MeralElRamahiMD: Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP):
      - 65%

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 10 months ago
      Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP): - 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment - 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4
      RT @RHEUMarampa: How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20

      sheila RHEUMarampa

      4 years 10 months ago
      How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20
      RT @RetamozoSole: Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Pa
      4 years 10 months ago
      Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp
      RT @RHEUMarampa: Accdg to this study, no association was found between IFN levels and cognitive function in SLE pts (eve

      sheila RHEUMarampa

      4 years 10 months ago
      Accdg to this study, no association was found between IFN levels and cognitive function in SLE pts (even after considering factors like SLE dse duration) Interesting! @RheumNow #ACR20 abs1788 @ZahiTouma https://t.co/F4j8H1CWJ9
      RT @ejdein1: Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #A

      Eric Dein ejdein1

      4 years 10 months ago

      Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.

      RT @Janetbirdope: #osteoarthritis Rx with #tanezumab - analgesic or DMOAD? RCT in knee OA of 3021 pts & only 1312 co

      Janet Pope Janetbirdope

      4 years 10 months ago
      #osteoarthritis Rx with #tanezumab - analgesic or DMOAD? RCT in knee OA of 3021 pts & only 1312 completed Rx. Tanezumab > improvement in pain v NSAIDs but NO diff in MCII and pt acceptable symptoms (PASS) over time #ACR20 #ACRbest abstr#1641 @RheumNow @CRASCRRheum https://t.co/x75ncz16uP
      ABCs of RA: Panel Discussion with Dr. Jonathan Kay

      They're back: from Dublin, Melbourne, Boston, Baltimore and Quezon City, Philippines to discuss top abstracts in the area of RA at the end of day three (Sunday) at ACR 2020, led by Dr. Jonathan Kay. Panelists: Dr. Sheila Reyes, Dr. David Liew, Dr. Eric Dein and Dr. Richard Conway.

      Roundtable on Gout: What's Hot at ACR 2020 with Gout Faculty

      Drs. Michael Pillinger, Naomi Schlesinger and Robert Keenan discuss the hot topics in Gout in a panel discussion at ACR 2020.

      ×